"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors Clinically relevant actionable mutations were identified ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level Disparities A total of 7,413 tumor specimens were tested. The ...
Yesterday, the U.S. Food and Drug Administration approved the first blood-based genetic test that can detect gene mutations in non-small cell lung cancer patients. The cobas EGFR Mutation Test v2 is a ...
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...
In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical ...
It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results